Ionis Pharmaceuticals, Inc.

IONS

Healthcare

$76.73+1.97%vs prev close

$31.66

$86.74

52W RangeNear 52W High

+2.96 (+4.01%)Past 1M

Price

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

275,702

Portfolio Weight

0.16%

in ETF 1.72%

Est. Value

$21M

30D Net

Ray DalioBridgewater Associates

Increased

67,706

Portfolio Weight

0.02%

Est. Value

$5M

vs Prev Quarter

+55% (44K→68K)

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$100.74

vs Current ▲ +31.3% upside

Current$76.73

Low ~ High$47.00 ~ $130.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

RBC Capital

Outperform

$100.00

+30.33%

$74.76

Maintain

2026-04-30

Barclays

Overweight

$115.00

+49.88%

$74.76

Maintain

2026-04-30

HC Wainwright & Co.

Buy

$125.00

+62.91%

$74.76

Maintain

2026-04-30

TD Cowen

Buy

$108.00

+40.75%

$74.09

Maintain

2026-04-23

Canaccord Genuity

Buy

$110.00

+43.36%

$74.78

Upgrade

2026-04-21

1 / 1

Avg Target

$100.74

vs Current ▲ +31.3% upside

Buy

24 analysts

Strong Buy 8Buy 11Hold 5

Low $47.00

Current $76.73

High $130.00

Firm	Position	Target	Upside	Close	Action	Date
RBC Capital	Outperform	$100.00	+30.33%	$74.76	Maintain	26.04.30
Barclays	Overweight	$115.00	+49.88%	$74.76	Maintain	26.04.30
HC Wainwright & Co.	Buy	$125.00	+62.91%	$74.76	Maintain	26.04.30
TD Cowen	Buy	$108.00	+40.75%	$74.09	Maintain	26.04.23
Canaccord Genuity	Buy	$110.00	+43.36%	$74.78	Upgrade	26.04.21

1 / 1

Price Information

Previous Close$75.25

Open$75.63

Day Range$75.29 - $77.41

52-Week Range$31.66 - $86.74

1-Year Change127.55%

Trading Volume

Volume967,234

Avg Volume (3mo)2,094,715

Valuation

Market Cap12.7B

Book Value$2.96

Shares Outstanding165,262,556

Financials

Revenue (TTM)1.1B

Net Income-326,976,992

EPS$-2.01

EBITDA-338,648,992

Profitability

P/E Ratio-

P/B Ratio25.90

Return on Equity (ROE)-67.62%

Return on Assets (ROA)-7.03%

Profit Margin-30.90%

EV/EBITDA-38.59

Beta0.38

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)57.37

Company Overview

Ionis Pharmaceuticals is a commercial-stage biotechnology company specializing in RNA-targeted medicines. Their main products include treatments for rare genetic neurological diseases like spinal muscular atrophy (SMA), hereditary transthyretin-mediated amyloidosis (ATTRv-PN), and ALS, as well as conditions like familial chylomicronemia syndrome (FCS). Ionis holds a significant position in the market for developing innovative therapies for these unmet medical needs.

P/B

25.90

High valuation

ROE

-67.6%

Persistent loss

Beta

0.38

Low volatility

RSI(14)

57.4

Neutral zone

AI-generated summary. Not investment advice.